Seres Therapeutics Valuation
| 1S9 Stock | EUR 0.84 0.01 1.20% |
Today, the company appears to be overvalued. Seres Therapeutics has a current Real Value of €0.67 per share. The regular price of the company is €0.84. Our model measures the value of Seres Therapeutics from inspecting the company fundamentals such as Current Valuation of 582.79 M, shares owned by insiders of 6.66 %, and Return On Equity of -1.9 as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Seres Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Seres Therapeutics is based on 3 months time horizon. Increasing Seres Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Seres stock is determined by what a typical buyer is willing to pay for full or partial control of Seres Therapeutics. Since Seres Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Seres Stock. However, Seres Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.84 | Real 0.67 | Hype 0.83 |
The real value of Seres Stock, also known as its intrinsic value, is the underlying worth of Seres Therapeutics Company, which is reflected in its stock price. It is based on Seres Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Seres Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Seres Therapeutics helps investors to forecast how Seres stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Seres Therapeutics more accurately as focusing exclusively on Seres Therapeutics' fundamentals will not take into account other important factors: Seres Therapeutics Total Value Analysis
Seres Therapeutics is presently estimated to have takeover price of 582.79 M with market capitalization of 608.32 M, debt of 24.64 M, and cash on hands of 253.62 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Seres Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
582.79 M | 608.32 M | 24.64 M | 253.62 M |
Seres Therapeutics Investor Information
About 86.0% of the company shares are owned by institutions such as pension funds. The company recorded a loss per share of 2.18. Seres Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Seres Therapeutics' liquidity, profitability, solvency, and operating efficiency, Seres Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Seres Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Seres Therapeutics has an asset utilization ratio of 40.84 percent. This implies that the Company is making €0.41 for each dollar of assets. An increasing asset utilization means that Seres Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Seres Therapeutics Ownership Allocation
Seres Therapeutics shows a total of 124.59 Million outstanding shares. The majority of Seres Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Seres Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Seres Therapeutics. Please pay attention to any change in the institutional holdings of Seres Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Seres Therapeutics Profitability Analysis
The company reported the revenue of 144.93 M. Net Loss for the year was (65.58 M) with profit before overhead, payroll, taxes, and interest of 3.04 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Seres Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Seres Therapeutics and how it compares across the competition.
About Seres Therapeutics Valuation
The stock valuation mechanism determines Seres Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Seres Therapeutics. We calculate exposure to Seres Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Seres Therapeutics's related companies.Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. SERES THERAPEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 155 people.
8 Steps to conduct Seres Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Seres Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Seres Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Seres Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Seres Therapeutics' revenue streams: Identify Seres Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Seres Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Seres Therapeutics' growth potential: Evaluate Seres Therapeutics' management, business model, and growth potential.
- Determine Seres Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Seres Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Seres Stock analysis
When running Seres Therapeutics' price analysis, check to measure Seres Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seres Therapeutics is operating at the current time. Most of Seres Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seres Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seres Therapeutics' price. Additionally, you may evaluate how the addition of Seres Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| CEOs Directory Screen CEOs from public companies around the world |